Search Results - "Clarke‐Pearson, Daniel"

The limited utility of currently available venous thromboembolism risk assessment tools in gynecological oncology patients by Barber, Emma L., MD, Clarke-Pearson, Daniel L., MD

“…Background Use of risk assessment tools, such as the Caprini score or Rogers score, is recommended by national societies to stratify surgical patients by…”
Get full text

Prevention of venous thromboembolism in gynecologic oncology surgery by Barber, Emma L, MD, Clarke-Pearson, Daniel L, MD

“…Abstract Gynecologic oncology patients are at a high-risk of postoperative venous thromboembolism and these events are a source of major morbidity and…”
Get full text

Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroid tumors in premenopausal women: a decision analysis by Siedhoff, Matthew T., MD, MSCR, Wheeler, Stephanie B., PhD, MPH, Rutstein, Sarah E., BA, Geller, Elizabeth J., MD, Doll, Kemi M., MD, Wu, Jennifer M., MD, MPH, Clarke-Pearson, Daniel L., MD

“…Objective The purpose of this study was to model outcomes in laparoscopic hysterectomy with morcellation compared with abdominal hysterectomy for the presumed…”
Get full text

Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications by Siedhoff, Matthew T., MD, MSCR, Doll, Kemi M., MD, MSCR, Clarke-Pearson, Daniel L., MD, Rutstein, Sarah E., PhD

“…Previous decision analyses demonstrate the safety of minimally invasive hysterectomy for presumed benign fibroids, accounting for the risk of occult…”
Get full text

A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: A Gynecologic Oncology Group study by Carlson, Jay W, Kauderer, James, Walker, Joan L, Gold, Michael A, O'Malley, David, Tuller, Erin, Clarke–Pearson, Daniel L

“…Abstract Objectives To evaluate VH fibrin sealant's influence on lower extremity lymphedema after inguinal lymphadenectomy in vulvar cancer patients. Methods…”
Get full text

Surgical training in gynecologic oncology: Past, present, future by Hoffman, Mitchel S., Chi, Dennis S., Clarke-Pearson, Daniel L., Cliby, William, Creasman, William, Underwood, Paul B.

“…The purpose of this paper is to review the surgical care related to training in gynecologic oncology, from past, present and future perspectives. A marked…”
Get full text

Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study by Rose, Peter G, Ali, Shamshad, Watkins, Edwin, Thigpen, J Tate, Deppe, Gunter, Clarke-Pearson, Daniel L, Insalaco, Samuel

“…We report the long-term survival and toxicity of a randomized phase III study comparing cisplatin alone with cisplatin, flurouracil, and hydroxyurea versus…”
Get full text

Screening for Ovarian Cancer by Clarke-Pearson, Daniel L

“…A 56-year-old woman presents to her physician, requesting screening for ovarian cancer. She reports the recent death of a friend from ovarian cancer at the age…”
Get full text

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer by Cragun, Janiel M, Havrilesky, Laura J, Calingaert, Brian, Synan, Ingrid, Secord, Angeles Alvarez, Soper, John T, Clarke-Pearson, Daniel L, Berchuck, Andrew

“…Selective lymphadenectomy is widely accepted in the management of endometrial cancer. Purported benefits are individualization of adjuvant therapy based on…”
Get full text

Obesity is associated with worse quality of life in women with gynecologic malignancies: An opportunity to improve patient‐centered outcomes by Doll, Kemi M., Kalinowski, Alison K., Snavely, Anna C., Irwin, Debra E., Bensen, Jeannette T, Bae‐Jump, Victoria L., Kim, Kenneth H., Van Le, Linda, Clarke‐Pearson, Daniel L., Gehrig, Paola A.

“…BACKGROUND The objective of the current study was to evaluate the effect of obesity on pretreatment quality of life (QoL) in gynecologic oncology patients…”
Get full text

Peritoneal Washings After Power Morcellation in Laparoscopic Myomectomy: A Pilot Study by Toubia, Tarek, MD, Moulder, Janelle K., MD, Schiff, Lauren D., MD, Clarke-Pearson, Daniel, MD, O'Connor, Siobhan M., MD, Siedhoff, Matthew T., MD, MSCR

“…Abstract Study Objective To evaluate if peritoneal washings of the abdominopelvic cavity during laparoscopic myomectomy can detect leiomyoma cells after power…”
Get full text

Complications of Hysterectomy by Clarke-Pearson, Daniel L., Geller, Elizabeth J.

“…Hysterectomy is the most common gynecologic procedure performed in the United States, with more than 600,000 procedures performed each year. Complications of…”
Get full text

Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas by Rutstein, Sarah E., PhD, Siedhoff, Matthew T., MD, MSCR, Geller, Elizabeth J., MD, Doll, Kemi M., MD, Wu, Jennifer M., MD, MPH, Clarke-Pearson, Daniel L., MD, Wheeler, Stephanie B., PhD, MPH

“…Abstract Study Objective Hysterectomy for presumed leiomyomata is 1 of the most common surgical procedures performed in nonpregnant women in the United States…”
Get full text

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer by Rose, Peter G, Bundy, Brian N, Watkins, Edwin B, Thigpen, J. Tate, Deppe, Gunther, Maiman, Mitchell A, Clarke-Pearson, Daniel L, Insalaco, Sam

“…Cervical cancer is the second most frequent cancer among women worldwide and the most frequent cancer among women in Africa, Asia, and South America. 1 In the…”
Get full text

Venous Thromboembolism in Minimally Invasive Compared With Open Hysterectomy for Endometrial Cancer by Barber, Emma L., Gehrig, Paola A., Clarke-Pearson, Daniel L.

“…OBJECTIVE:To evaluate whether minimally invasive surgery for endometrial cancer is independently associated with a decreased odds of venous thromboembolism…”
Get full text

Gynecological Cancer Management: Identification, Diagnosis and Treatment by Clarke-Pearson, Daniel, Soper, John

“…This concise and practical guide enables the gynecologist to differentiate between benign and malignant gynecologic conditions to determine the best management…”
Get full text

The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer by Havrilesky, Laura J, Cragun, Janiel M, Calingaert, Brian, Alvarez Secord, Angeles, Valea, Fidel A, Clarke-Pearson, Daniel L, Berchuck, Andrew, Soper, John T

“…Abstract Objective The clinical significance and optimal management of patients with stage IIIA endometrial cancer are controversial. We sought to determine…”
Get full text

Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-Hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study by SPRIGGS, David R, BRADY, Mark F, VACCARELLO, Luis, CLARKE-PEARSON, Daniel L, BURGER, Robert A, MANNEL, Robert, BOGGESS, John F, LEE, Roger B, HANLY, Mark

“…This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian…”
Get full text

Cross-sectional survey of surgical practices among gynecologic oncologists in the United States by Straubhar, Alli M., Zhou, Qin, Iasonos, Alexia, Clarke-Pearson, Daniel L., Cliby, William A., Hoffman, Mitchel S., Chi, Dennis S.

“…We sought to document current surgical practices among gynecologic oncologists in the United States. In March/April 2020, we conducted a cross-sectional survey…”
Get full text

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer by Alberts, David S, Liu, P.Y, Hannigan, Edward V, O'Toole, Robert, Williams, Stephen D, Young, James A, Franklin, Ernest W, Clarke-Pearson, Daniel L, Malviya, Vinay K, DuBeshter, Brent, Adelson, Mark D, Hoskins, William J

“…Ovarian cancer, the leading cause of death from gynecologic cancer in the United States, is one of the few solid tumors in which the five-year survival rate…”
Get full text